Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
12/23/11 4 Statement of Changes in Beneficial Ownership
12/21/11 8-K Current report filing
12/19/11 3 Initial Statement of Beneficial Ownership
12/07/11 8-K Current report filing

Stock Quote

ACOR (Common Stock) $ 25.40 +0.00 (+0%) Volume: 509,976 MORE March 24, 2017

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.